Vitamin K2 (menaquinone-7)
Also called: MK-7, menaquinone-7, vitamin K2
Menaquinone-7 (MK-7) is one of the menaquinones (vitamin K2), forms of vitamin K that are predominantly of bacterial origin. Natto, a Japanese food of fermented soybeans, is a rich source. General vitamin K information is in the vitamin K entry.
- Category
- Vitamin
- Forms
- Menaquinone-7 (MK-7); menaquinone-7 dipropionate also appears on FDA's NDI list
- Strongest evidence
- C Limited
- Reviewed
- 2026-10-30
Class 2 Moderately studied in people. Eight randomized controlled trials of MK-7 alone were found: bone loss (2013), vascular or coronary calcification (2019, 2026), type 2 diabetes (2020, 2021, 2023), polycystic ovary syndrome (2020) and insulin sensitivity after menopause (2021). The six articles in the 2025 meta-analysis could not all be confirmed as distinct MK-7-alone trials. [3]
Fact-checked 2026-10-30 · How this guide is made
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.
What research has studied
Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.
CBones and joints1 topic
CHormones and reproduction1 topic
A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials
| Topic studied | Grade | What the evidence shows |
|---|---|---|
| Bone loss in healthy postmenopausal women | C | A 3-year RCT in 244 women (180 micrograms/day MK-7) reduced age-related decline in bone mineral density at the lumbar spine and femoral neck, but not the total hip, and favorably affected bone strength. [3] |
| Coronary artery calcification in symptomatic coronary artery disease | C | A 2-year RCT (VitaK-CAC; 180 patients randomized, 360 micrograms/day) found slower progression of coronary artery calcium scores with MK-7 than placebo (P = .02); no significant adverse effects were observed. [4] |
| Arterial calcification in type 2 diabetes with cardiovascular disease | C | A 6-month RCT (68 patients, 360 micrograms/day) found MK-7 did not reduce femoral arterial calcification; PET-measured activity tended to increase versus placebo (P = 0.06, not significant). [5] |
| Glycemic control and blood lipids | C | A 2025 meta-analysis of six RCTs reported lower insulin, HbA1c and HOMA-IR with MK-7, with high heterogeneity (I2 84-87%), and no meaningful effect on other measures; authors called for higher-quality trials. [2] |
| Osteoporosis risk (all vitamin K forms) | C | ODS states it is unclear whether supplementation with any form of vitamin K reduces the risk of osteoporosis; findings from clinical trials have been mixed. [1] |
Main constituents: Menaquinone-7 (MK-7), a menaquinone with an unsaturated isoprenyl side chain [1]
Amounts studied and limits
Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.
- 180 micrograms/day MK-7 for 3 years (postmenopausal women). [3]
- 360 micrograms/day MK-7 for 2 years (coronary artery disease). [4]
Upper limits
- Vitamin K (all forms) has no Tolerable Upper Intake Level because of its low potential for toxicity. Adequate Intakes for adults 19 and older: 120 micrograms/day (men) and 90 micrograms/day (women). [1]
Safety and side effects
- Liver (NIH LiverTox)Nothing found
No published information found in the sources checked.
Details and sources - Pregnancy and breastfeedingNothing found
No published information found in the sources checked.
Details and sources - Interactions with medicines1 listed
Warfarin and other anticoagulants
Details and sources - Cancer evaluations (IARC, NTP)1 found
Each names the exact material tested, which may differ from a supplement.
Details and sources - FDA new dietary ingredient notificationsNone on FDA's list
FDA does not approve dietary supplements. Each entry is one party's filing.
Details and sources - Dose in official monographsNone found
No published information found in the sources checked.
Details and sources
Interactions
| With | What happens |
|---|---|
| Warfarin and other anticoagulants | ODS: vitamin K can have a serious and potentially dangerous interaction with anticoagulants such as warfarin; people taking them need to maintain a consistent vitamin K intake, because sudden changes can increase or decrease the anticoagulant effect. [1] |
Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.
Regulatory status
Safety, quality and supply profile
Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.
Compounds responsible
Compounds the sources name as the main or characteristic actives.
- Menaquinone-7 (MK-7) Menaquinone (vitamin K2) [P5]
US status
What FDA's published records show. FDA does not approve dietary supplements.
- No NDI notification naming menaquinone-7 itself was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30); 2 entries name menaquinone-7 dipropionate (earliest NDI 1085 submitted 2018-08-13; most recent NDI 1112 submitted 2019-05-29). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P1]
Cancer evaluations (IARC and NTP)
Evaluations name the exact material tested, which may differ from a supplement.
- IARC lists 'Vitamin K substances' (CAS 12001-79-5) in Group 3, not classifiable as to carcinogenicity to humans (Volume 76, published 2000, evaluated 1999); the entry does not name menaquinone-7 separately. [P2]
- The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of menaquinone-7 (checked 2026-10-30). [P3]
Liver (NIH LiverTox)
- No published information found in the sources checked.
Interactions with medicines
- Warfarin and other anticoagulants: ODS: vitamin K can have a serious and potentially dangerous interaction with anticoagulants such as warfarin; people taking them need to maintain a consistent vitamin K intake, because sudden changes can increase or decrease the anticoagulant effect. [P5]
Alcohol
- No published information found in the sources checked.
Interactions with other herbs and supplements
- No published information found in the sources checked.
Adulteration and substitution
- No published information found in the sources checked.
What a certificate of analysis should cover
Tests a quality specification for this material would include, with the reason for each.
- Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
Supply and conservation
- No published information found in the sources checked.
Absorption in people
- ODS: one study found both phytonadione and MK-7 supplements are well absorbed, but MK-7 has a longer half-life. [P5]
- Sato et al. (2012): a single 420-microgram dose of MK-7 with breakfast reached maximal serum level at 6 h and was detected up to 48 h; the same dose of MK-4 was not detectable in serum. [P6]
Formulations studied to change absorption
Human data only.
- No published information found in the sources checked.
Dose in official monographs
As the monograph states it, for its jurisdiction; not personal advice.
- No published information found in the sources checked.
Pregnancy and breastfeeding
- No published information found in the sources checked.
Sources for this profile
- FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
- IARC Monographs. List of Classifications (last update 2026-07-23; checked 2026-10-30): entry 'Vitamin K substances', 2026-07-23. monographs.iarc.who.int
- National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
- eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (current text, retrieved 2026-10-30), 2026-10-30. ecfr.gov
- NIH Office of Dietary Supplements. Vitamin K: Fact Sheet for Health Professionals (Updated: October 22, 2026), 2026-10-22. ods.od.nih.gov
- Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J 2012;11:93 (PMID 23140417), 2012-11-12. pubmed.ncbi.nlm.nih.gov
Sources
- NIH Office of Dietary Supplements. Vitamin K: Fact Sheet for Health Professionals (Updated: October 22, 2026), 2026-10-22. ods.od.nih.gov
- Nikpayam O, et al. Effect of menaquinone-7 (MK-7) supplementation on anthropometric measurements, glycemic indices, and lipid profiles: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Other Lipid Mediat 2025;177:106970 (PMID 40054729), 2025-03. pubmed.ncbi.nlm.nih.gov
- Knapen MH, et al. Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporos Int 2013;24(9):2499-507 (PMID 23525894), 2013-09. pubmed.ncbi.nlm.nih.gov
- Vossen LM, et al. Two years of menaquinone-7 supplementation and coronary artery calcification: a randomized clinical trial. JAMA Cardiol 2026;11(8):719-726 (PMID 42268593), 2026-08-01. pubmed.ncbi.nlm.nih.gov
- Zwakenberg SR, et al. The effect of menaquinone-7 supplementation on vascular calcification in patients with diabetes: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2019;110(4):883-890 (PMID 31387121), 2019-10-01. pubmed.ncbi.nlm.nih.gov
- Karamzad N, et al. Effects of MK-7 supplementation on glycemic status, anthropometric indices and lipid profile in patients with type 2 diabetes: a randomized controlled trial. Diabetes Metab Syndr Obes 2020;13:2239-2249 (PMID 32617013), 2020-06-26. pubmed.ncbi.nlm.nih.gov
- Tarkesh F, et al. Beneficial health effects of menaquinone-7 on body composition, glycemic indices, lipid profile, and endocrine markers in polycystic ovary syndrome patients. Food Sci Nutr 2020;8(10):5612-5621 (PMID 33133563), 2020-09-04. pubmed.ncbi.nlm.nih.gov
- Rahimi Sakak F, et al. Glycemic control improvement in individuals with type 2 diabetes with vitamin K2 supplementation: a randomized controlled trial. Eur J Nutr 2021;60(5):2495-2506 (PMID 33159574), 2021-08. pubmed.ncbi.nlm.nih.gov
- Rønn SH, et al. Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial. Eur J Clin Nutr 2021;75(11):1661-1667 (PMID 33664429), 2021-11. pubmed.ncbi.nlm.nih.gov
- Zhang Y, et al. Vitamin K2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites. BMC Med 2023;21(1):174 (PMID 37147641), 2023-05-05. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (Content current as of 08/27/2026), 2026-08-27. fda.gov
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
More in vitamin: Benfotiamine · Biotin · Folate (folic acid) · Methylfolate (L-5-MTHF) · Niacin (vitamin B3) · Nicotinamide riboside · Pantothenic acid (vitamin B5) · Riboflavin (vitamin B2) · All entries A–Z · How to judge a supplement
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.